Coronavirus (COVID-19)
Learn more
Phase II Trial of Single-Agent Nivolumab in Patients With Microsatellite Unstable/Mismatch Repair Deficient/Hypermutated Uterine Cancer
Eligibility Criteria:
This study is for patients age 18 and older.
Available at: Hartford Hospital, and Hospital of Central Connecticut
Referral Line: 860.972.4700
Get the latest healthcare news directly in your inbox.
Sign up for text alerts / Text MoreLife to 31996.